Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)

Background: The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed. Case: We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC...

Full description

Bibliographic Details
Main Authors: Alessandro D. Santin, Stefania Bellone, Natalia Buza, Peter E. Schwartz
Format: Article
Language:English
Published: Elsevier 2017-02-01
Series:Gynecologic Oncology Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578916300881